GILD Gilead Sciences, Inc. - Fundamental Analysis
NEUTRAL
GILD Stock | Fundamental Analysis & Investment Insights
NASDAQ
•
Healthcare
•
Drug Manufacturers - General
Current Price
$121.6
Analyst Target
$132.38
+8.9% Upside
52W High
$128.7
52W Low
$88.57
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 04, 2026
Market cap
$150.88B
P/E
18.82
ROE
40.7%
Profit margin
27.9%
Debt/Equity
1.16
Dividend yield
2.6%
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
78%
Analysis Accuracy
Gilead Sciences exhibits strong financial health with an exceptionally high Altman Z-Score (>256 billion), indicating negligible bankruptcy risk, but a weak Piotroski F-Score of 4/9 suggests moderate operational and financial stability. The company demonstrates robust profitability, including a 45.23% operating margin and 40.71% ROE, while trading below analyst target price of $132.38 despite a bearish technical trend. Earnings growth is impressive year-over-year at 143%, though revenue growth remains modest at 3%. Insider selling activity and a low technical trend score counterbalance strong valuation metrics and dividend sustainability.
Key Strengths
Exceptionally high Altman Z-Score indicates near-zero bankruptcy risk
Strong profitability with 45.23% operating margin and 40.71% ROE
Attractive dividend yield of 2.60% with sustainable 48.61% payout ratio
Significant earnings growth: 143% YoY and 143.6% Q/Q
Trading below analyst consensus target price of $132.38
Key Risks
Weak Piotroski F-Score of 4/9 indicates potential deterioration in financial controls or performance trends
High insider selling: $16.86M in sales over last 6 months with zero buys
Low technical trend score of 10/100 signals strong near-term bearish momentum
Valuation premiums: P/E of 18.82 vs sector average of 37.07, but Price/Book of 7.01 is elevated
Limited data availability for key metrics (EV, cash, debt, shares) raises transparency concerns
AI Fair Value Estimate
Based on comprehensive analysis
$132.38
+8.9% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
70
Strong
72
80
65
58
75
AI Verdict
Moderately positive outlook with strong fundamentals offset by weak technicals and insider sentiment
Key drivers: High Altman Z-Score, Strong ROE and operating margins, Earnings growth acceleration, Bearish insider activity, Low technical trend
Confidence
85%
Value
72/100
Ref P/E, PEG, Graham Number
Positives
- Forward P/E of 13.90 is below current P/E of 18.82, suggesting earnings growth expectations
- Trading below analyst target of $132.38
- Graham Number ($50.21) significantly below current price, but justified by growth and profitability
Watchpoints
- Price/Book of 7.01 is high relative to historical norms
- Current P/E above forward P/E implies multiple contraction risk
Future
80/100
Ref Growth rates
Positives
- Exceptional YoY earnings growth of 143%
- Q/Q earnings growth of 143.60% indicates accelerating profitability
- Forward P/E of 13.90 suggests favorable future earnings expectations
Watchpoints
- Revenue growth of only 3.00% YoY limits top-line expansion potential
Past
65/100
Ref Historical trends
Positives
- Consistent earnings beats in 3 of last 4 quarters
- Long-term price appreciation: +145.1% over 5 years
- Historical ROE consistently above 35%
Watchpoints
- Earnings surprises have declined from highs of +48.7% to recent +1.9%
- Mixed quarterly performance with several negative surprises in prior years
Health
58/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Altman Z-Score >256 billion indicates extreme financial stability
- Current ratio of 1.45 and quick ratio of 1.10 show adequate short-term liquidity
- Debt/Equity of 1.16 is manageable and below sector average of 1.21
Watchpoints
- Piotroski F-Score of 4/9 indicates weak financial trajectory
- Missing key data on cash, debt, and enterprise value limits full health assessment
Dividend
75/100
Ref Yield, Payout
Positives
- Dividend yield of 2.60% is attractive in current market environment
- Payout ratio of 48.61% is sustainable and leaves room for increases
- Dividend strength score of 50/100 indicates moderate reliability
Watchpoints
- No 5-year average yield data available for trend analysis
- Insider selling may signal caution around dividend sustainability
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$121.6
Analyst Target
$132.38
Upside/Downside
+8.9%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for GILD and closest competitors.
Updated 2026-01-02
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
GILD
Gilead Sciences, Inc.
Primary
|
+145.1% | +58.2% | +36.0% | +10.3% | -2.1% | -2.5% |
|
PFE
Pfizer Inc.
Peer
|
-12.7% | -41.6% | +1.5% | +2.7% | -1.5% | +0.4% |
|
BSX
Boston Scientific Corporation
Peer
|
+168.5% | +105.8% | +6.0% | -9.2% | -3.9% | -1.4% |
|
DHR
Danaher Corporation
Peer
|
+19.0% | +0.6% | +0.9% | +13.7% | +1.0% | +0.0% |
|
SYK
Stryker Corporation
Peer
|
+53.4% | +45.7% | -2.0% | -11.5% | -4.6% | -1.5% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
18.82
Forward P/E
13.9
PEG Ratio
N/A
P/B Ratio
7.01
P/S Ratio
5.19
EV/Revenue
5.75
EV/EBITDA
11.83
Market Cap
$150.88B
Profitability
Profit margins and return metrics
Profit Margin
27.88%
Operating Margin
45.23%
Gross Margin
78.72%
ROE
40.71%
ROA
12.57%
Growth
Revenue and earnings growth rates
Revenue Growth
+3.0%
Earnings Growth
+143.0%
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
+143.6%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
1.16
Moderate
Current Ratio
1.45
Good
Quick Ratio
1.1
Good
Cash/Share
$6.84
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-10
$N/A
2025-10-30
$2.47
+15.7% surprise
2025-08-07
$2.01
+2.7% surprise
2025-04-24
$1.81
+1.9% surprise
Healthcare Sector Comparison
Comparing GILD against 42 companies in the Healthcare sector
(5 bullish, 31 neutral, 6 bearish)
P/E Ratio
18.82
This Stock
vs
252.74
Sector Avg
-92.6%
(Discount)
Return on Equity (ROE)
40.71%
This Stock
vs
25.54%
Sector Avg
+59.4%
(Excellent)
Profit Margin
27.88%
This Stock
vs
9.99%
Sector Avg
+179.2%
(Superior)
Debt to Equity
1.16
This Stock
vs
0.92
Sector Avg
+26.3%
(Higher)
Revenue Growth
3.0%
This Stock
vs
9.8%
Sector Avg
-69.4%
(Slower)
Current Ratio
1.45
This Stock
vs
2.27
Sector Avg
-36.1%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
GILD
Gilead Sciences, Inc.
|
NEUTRAL | $150.88B | 18.82 | 40.7% | 27.9% | $121.6 | |
|
PFE
Pfizer Inc.
|
NEUTRAL | $143.17B | 14.64 | 10.6% | 15.7% | $25.18 | |
|
BSX
Boston Scientific Corporation
|
NEUTRAL | $140.4B | 50.65 | 12.5% | 14.4% | $94.71 | |
|
DHR
Danaher Corporation
|
NEUTRAL | $164.98B | 47.41 | 6.8% | 14.4% | $230.4 | |
|
SYK
Stryker Corporation
|
NEUTRAL | $133.15B | 45.63 | 14.0% | 12.1% | $348.18 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-29 | O'DAY DANIEL PATRICK | Chief Executive Officer | Sale | 10,000 | $1,248,272 |
| 2025-12-15 | MERCIER JOHANNA | Officer | Sale | 3,000 | $366,000 |
| 2025-12-15 | DICKINSON ANDREW D | Chief Financial Officer | Sale | 3,000 | $366,000 |
| 2025-12-10 | MERCIER JOHANNA | Officer | Stock Award | 3,842 | - |
| 2025-12-10 | O'DAY DANIEL PATRICK | Chief Executive Officer | Stock Award | 10,426 | - |
| 2025-12-10 | DICKINSON ANDREW D | Chief Financial Officer | Stock Award | 3,693 | - |
| 2025-11-28 | BLUESTONE JEFFREY | Director | Option Exercise | 5,000 | $324,600 |
| 2025-11-28 | KRAMER KELLY A | Director | Option Exercise | 5,611 | $454,491 |
| 2025-11-28 | KRAMER KELLY A | Director | Sale | 5,611 | $713,186 |
| 2025-11-28 | O'DAY DANIEL PATRICK | Chief Executive Officer | Sale | 10,000 | $1,265,444 |
| 2025-11-28 | BLUESTONE JEFFREY | Director | Sale | 5,000 | $625,400 |
| 2025-11-17 | MERCIER JOHANNA | Officer | Option Exercise | 25,000 | $1,666,000 |
| 2025-11-17 | MERCIER JOHANNA | Officer | Sale | 28,000 | $3,524,173 |
| 2025-11-17 | DICKINSON ANDREW D | Chief Financial Officer | Sale | 2,500 | $313,075 |
| 2025-11-12 | TELMAN DEBORAH H | General Counsel | Option Exercise | 53,646 | $3,505,885 |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
26 analysts
Morgan Stanley
2025-12-12
Overweight
Overweight
Wells Fargo
2025-12-10
Overweight
Overweight
Needham
2025-11-13
Buy
Buy
Scotiabank
2025-11-13
Sector Outperform
Truist Securities
2025-11-03
Buy
Buy
Wells Fargo
2025-10-31
Overweight
Overweight
JP Morgan
2025-10-31
Overweight
Overweight
RBC Capital
2025-10-31
Sector Perform
Sector Perform
Cantor Fitzgerald
2025-10-31
Overweight
Overweight
Needham
2025-10-31
Buy
Buy